US2007037878A1PendingUtilityA1

Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease

63
Individually held — no corporate assignee on recordPriority: Dec 17, 1998Filed: Oct 18, 2006Published: Feb 15, 2007
Est. expiryDec 17, 2018(expired)· nominal 20-yr term from priority
Inventors:William J. Wechter
A61P 43/00A61P 9/08A61P 7/02A61P 9/10A61P 9/00A61P 9/04A61P 9/12A61P 35/00A61P 3/06A61P 37/04A61P 25/00A61P 27/02A61P 13/12A61K 45/06A61P 1/16A61P 21/00A61K 31/355
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

Claims

exact text as granted — not AI-modified
1 . A method of treating an ischemic condition in a subject, comprising: 
 identifying a subject having an ischemic condition; and    providing to said subject a composition that comprises tocopherols, at least 50% of said tocopherols being γ-tocopherol.    
     
     
         2 . The method of  claim 1 , wherein said ischemic condition is associated with the circulatory system.  
     
     
         3 . The method of  claim 1 , wherein said ischemic condition is associated with the cardiovascular system.  
     
     
         4 . The method of  claim 1 , wherein said ischemic condition is associated with the liver.  
     
     
         5 . The method of  claim 1 , wherein said ischemic condition is associated with the kidney.  
     
     
         6 . The method of  claim 1 , wherein said ischemic condition is associated with diabetes.  
     
     
         7 . The method of  claim 1 , wherein said ischemic condition is associated with thromboembolic disease.  
     
     
         8 . The method of  claim 1 , wherein said ischemic condition is associated with the brain.  
     
     
         9 . The method of  claim 1 , wherein said ischemic condition is associated with the nervous system.  
     
     
         10 . The method of  claim 1 , wherein said ischemic condition is associated with the eye.  
     
     
         11 . The method of  claim 1 , wherein at least 60% of said tocopherols are γ-tocopherol.  
     
     
         12 . The method of  claim 1 , wherein at least 65% of said tocopherols are γ-tocopherol.  
     
     
         13 . The method of  claim 1 , wherein at least 70% of said tocopherols are γ-tocopherol.  
     
     
         14 . The method of  claim 1 , wherein 55% to 95% of said tocopherols are γ-tocopherol.  
     
     
         15 . The method of  claim 1 , wherein 50% of said tocopherols are γ-tocopherol.  
     
     
         16 . The method of  claim 1 , wherein 55% of said tocopherols are γ-tocopherol.  
     
     
         17 . The method of  claim 1 , wherein 60% of said tocopherols are γ-tocopherol.  
     
     
         18 . The method of  claim 1 , wherein 65% of said tocopherols are γ-tocopherol.  
     
     
         19 . The method of  claim 1 , wherein 70% of said tocopherols are γ-tocopherol.  
     
     
         20 . The method of  claim 1 , wherein 75% of said tocopherols are γ-tocopherol.  
     
     
         21 . The method of  claim 1 , wherein 95% of said tocopherols are γ-tocopherol.  
     
     
         22 . The method of  claim 1 , wherein 100% of said tocopherols are γ-tocopherol.  
     
     
         23 . A method of treating a condition associated with a vitamin E deficiency in a mammal, comprising: 
 identifying a mammal with a condition associated with a vitamin E deficiency; and    providing to said mammal a composition that comprises tocopherols, at least 70% of said tocopherols being γ-tocopherol.    
     
     
         24 . The method of  claim 23 , wherein 70% of said tocopherols are γ-tocopherol.  
     
     
         25 . The method of  claim 23 , wherein 75% of said tocopherols are γ-tocopherol.  
     
     
         26 . The method of  claim 23 , wherein 95% of said tocopherols are γ-tocopherol.  
     
     
         27 . The method of  claim 23 , wherein 100% of said tocopherols are γ-tocopherol.  
     
     
         28 . A method of treating a condition associated with a vitamin E deficiency in a mammal, comprising: 
 identifying a mammal with a condition associated with a vitamin E deficiency; and    providing to said mammal a composition that comprises 5% to 95% LLU-α.    
     
     
         29 . The method of  claim 28 , wherein the composition comprises 25% to 60% LLU-α.  
     
     
         30 . The method of  claim 28 , wherein the composition comprises no more than 50% LLU-α.  
     
     
         31 . A method of improving a condition associated with a vitamin E deficiency in a mammal, comprising: 
 identifying a mammal with a condition associated with a vitamin E deficiency; and    providing to said mammal a composition that comprises tocopherols, at least 70% of said tocopherols being γ-tocopherol.    
     
     
         32 . The method of  claim 31 , wherein 70% of said tocopherols are γ-tocopherol.  
     
     
         33 . The method of  claim 31 , wherein 75% of said tocopherols are γ-tocopherol.  
     
     
         34 . The method of  claim 31 , wherein 95% of said tocopherols are γ-tocopherol.  
     
     
         35 . The method of  claim 31 , wherein 100% of said tocopherols are γ-tocopherol.  
     
     
         36 . A method of improving a condition associated with a vitamin E deficiency in a mammal, comprising: 
 identifying a mammal with a condition associated with a vitamin E deficiency; and    providing to said mammal a composition that comprises 5% to 95% LLU-α.    
     
     
         37 . The method of  claim 36 , wherein the composition comprises 25% to 60% LLU-α.  
     
     
         38 . The method of  claim 36 , wherein the composition comprises no more than 50% LLU-α.

Join the waitlist — get patent alerts

Track US2007037878A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.